Population analysis of a 24-h paclitaxel infusion in advanced endometrial cancer: A gynaecological oncology group study

British Journal of Clinical Pharmacology

Volumn 62, Issue 1, 2006, Pages 56-70

  Mould, Diane R ^a   Fleming, Gini F ^b   Darcy, Kathleen M ^c   Spriggs, David ^d  

^a Projections Research Inc   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

24 h paclitaxel; Advanced endometrial cancer; AUC; Pharmacokinetics; Survival; Toxicity

Indexed keywords

ASPARTATE AMINOTRANSFERASE; CISPLATIN; CYTOCHROME P450; DOXORUBICIN; PACLITAXEL;

ADULT; AGE; AGED; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BAYES THEOREM; BODY WEIGHT; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EXPOSURE; DRUG INFUSION; ENDOMETRIUM CANCER; FEMALE; GRANULOCYTOPENIA; HUMAN; LIQUID CHROMATOGRAPHY; LIVER TOXICITY; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; ONCOLOGY; PLASMA; PRIORITY JOURNAL; PROTEIN SECRETION; RANDOMIZED CONTROLLED TRIAL; SAMPLING; SIDE EFFECT; SURVIVAL; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; DOXORUBICIN; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; PACLITAXEL; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 33746911953     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2006.02718.x     Document Type: Article

References (60)

1. Rowinsky EK, Donehower RC. Drug therapy: paclitaxel (taxol). N Engl J Med 2003; 332: 1004-12.
2. Chan S, Gerson B. Free drug monitoring. Clin Lab Med 1987; 7: 279-87.
3. Kumar GN, Walle UK, Bhalla KN, Walle T. Binding of taxol to human plasma, albumin and alpha 1-acid glycoprotein. Res Commun Chem Pathol Pharmacol 1993; 80: 337-44.
4. van Tellingen O, Huizing MT, Panday VR, Schellens JH, Nooijen WJ, Beijnen JH. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. Br J Cancer 1999; 81: 330-5.
5. Barre J, Didey F, Delion F, Tillement JP. Problems in therapeutic drug monitoring. Free Drug Level Monitoring 1988; 10: 133-45.
6. Brouwer E, Verweij J, De Bruijn P, Loos WJ, Pillay M, Buijs D, Sparreboom A. Measurement of fraction unbound paclitaxel in human plasma. Drug Metab Dispos 2000; 28: 1141-5.
7. Gianni L, Kearns CM, Giani A, Capri G, Vigano L, Lacatelli A, Bonadonna G, Egorin MJ. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 1995; 13: 180-90.
8. Sonnichsen DS, Hurwitz CA, Pratt CB, Shuster JJ, Relling MV. Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. J Clin Oncol 1994; 12: 532-8.
9. Karlsson MO, Molnar V, Freijs A, Nygren P, Bergh J, Larsson R. Pharmacokinetic models for the saturable distribution of paclitaxel. Drug Metab Dispos 1999; 27: 1220-3.
10. van Zuylen L, Karlsson MO, Verweij J, Brouwer E, de Bruijn P, Nooter K, Stoter G, Sparreboom A. Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles. Cancer Chemother Pharmacol 2001; 47: 309-18.
11. Sparreboom A, van Zuylen L, Brouwer E, Loos WJ, de Bruijn P, Gelderblom H, Pillay M, Nooter K, Stoter G, Verweij J. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 1999; 59: 1454-7.
12. Brown T, Havlin K, Weiss G, Cagnola J, Koeller J, Kuhn J, Rizzo J, Craig J, Phillips J, Von Hoff D. A phase I trial of taxol given by a 6 hour intravenous infusion. J Clin Oncol 1991; 9: 1261-7.
13. Weirnik PH, Schwartz EL, Einzig A, Stauman JJ, Lipton RB, Paietta E. Phase I trial of taxol given as a 24 hour infusion every 21 days; responses observed in metastatic melanoma. J Clin Oncol 1991; 47: 2486-93.
14. Callies S, de Alwis DP, Harris A, Vasey P, Beijnen JH, Schellens JH, Burgess M, Aarons L. A population pharmacokinetic model for paclitaxel in the presence of a novel P-gp modulator, Zosuquidar Trihydrochloride (LY335979). Br J Clin Pharmacol 2003; 56: 46-56. Erratum in Br J Clin Pharmacol 2003; 56: 463.
15. Henningsson A, Karlsson MO, Vigano L, Gianni L, Verweij J, Sparreboom A. Mechanism-based pharmacokinetic model for paclitaxel. J Clin Oncol 2001; 19: 4065-73.
16. Rowinsky EK, Eisenhauer EA, Chaudry V, Arbuck SA, Donehower RC. Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 1993; 20 (Suppl. 3): 1-15.
17. Rowinsky EK, Jiroutek M, Bonomi P, Johnson D, Baker S. Paclitaxel steady-state plasma concentrations as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin. Clin Cancer Res 1999; 5: 767-74.
18. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles L, van der Burg ME, Kerr I, Vermorken JB, Buser K, Columbo N. European Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high dose versus low dose and long versus short infusion. J Clin Oncol 1994; 12: 654-66.
19. Henningsson A, Sparreboom A, Sandstrom M, Freijs A, Larsson R, Bergh J, Nygren P, Karlsson MO. Population pharmacokinetic modeling of unbound and total plasma concentration of paclitaxel in cancer patients. Eur J Cancer 2003; 39: 1105-14.
20. Karlsson MO, Molnar V, Bergh J, Freijs A, Larsson R. A general model for time-dissociated pharmacokinetic-pharmacodynamic relationship exemplified by paclitaxel myelosuppression. Clin Pharmacol Ther 1998; 63: 11-25.
21. Fleming GF, Filiaci VL, Bentley RC, Herzog T, Sorosky J, Vaccarello L, Gallion H. Phase III randomized trial of doxorubicin+cisplatin versus doxorubicin+24-hour paclitaxel+filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. Ann Oncol 2004; 15: 1173-8.
22. Sonnichsen DS, Relling MV. Clinical pharmacokinetics of paclitaxel. Clin Pharmacokinet 1994; 27: 256-69.
23. Kelly WK, Zhu AX, Scher H, Curley T, Fallon M, Slovin S, Schwartz L, Larson S, Tong W, Hartley-Asp B, Pellizzoni C, Rocchetti M. Dose escalation study of intravenous estramustine phosphate in combination with paclitaxel and carboplatin in patients with advanced prostate cancer. Clin Cancer Res 2003; 9: 2098-107.
24. Boeckmann AJ, Beal SL, Sheiner LB. NONMEM Users Guide; Parts I-VIII. San Francisco: UCSF 1998.
25. Sheiner LB, Rosenberg B, Marathe VV. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokin Biopharm 1977; 5: 445-79.
26. Sheiner LB, Beal SL, Rosenberg GB, Matre V. Forecasting individual pharmacokinetics. Clin Pharmacol Ther 1979; 36: 294-305.
27. Beal SL, Sheiner LB. The NONMEM system. Am Stat 1980; 34: 118.
28. Sheiner LB, Beal SL. Bayesian individualization of pharmacokinetics: simple implementation and comparison with NON-Bayesian methods. J Pharm Sci 1982; 71: 1344-8.
29. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
30. Kirkpatrick CM, Duffull SB, Begg EJ. Pharmacokinetics of gentamicin in 957 patients with varying renal function dosed once daily. Br J Clin Pharmacol 1999; 47: 637-43.
31. DuBois D, DuBois EF. A formula to estimate the approximate surface area if height and weight are known. Arch Intern Med 1916; 17: 863-71.
32. Holford NHG. A size standard for pharmacokinetics. Clin Pharmacokin 1996; 30: 329-32.
33. Anderson BJ, McKee D, Holford NHG. Size, myths and the clinical pharmacokinetics of analgesia in paediatric patients. Clin Pharmacokin 1997; 33: 313-27.
34. Wade JR, Beal SL, Sambol NC. Interaction between structural, statistical, and covariate models in population pharmacokinetic analysis. J Pharmacokinet Biopharm 1994; 22: 165-77.
35. Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic-pharmacodynamic models. J Pharmacokinet Biopharm 1992; 20: 511-28.
36. Wahlby U, Jonsson EN, Karlsson MO. Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodynam 2001; 28: 231-52.
37. Gobburu JVS, Lawrence J. Application of resampling techniques to estimate exact significance levels for covariate selection during nonlinear mixed effects model building: some inferences. Pharmaceut Res 2002; 19: 92-8.
38. Lin LI. A concordance coefficient to evaluate reproducibility. Biometrics 1989; 45: 255-68.
39. Yano Y, Beal SL, Sheiner LB. Evaluating pharmacokinetic/pharmacodynamic models using the predictive check. J Pharmacokinet Pharmacodyn 2001; 28: 171-92.
40. Karlsson MO. Model-Building Diagnostics. DIA Meeting, December 5-6, 2005; Philadelphia PA.
41. de Jonge ME, Huitema AD, Schellens JH, Schellens JH, Rodenhuis S, Beijnen JH. Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL. Br J Clin Pharmcol 2005; 59: 325-34.
42. Gustafson DL, Long ME, Bradshaw EL, Merz AL, Kerzic PJ. P450 induction alters paclitaxel pharmacokinetics and tissue distribution with multiple dosing. Cancer Chemother Pharmacol 2005; 56: 248-54.
43. Moreira A, Lobato R, Morais J, Silva S, Ribeiro J, Figueira A, Vale D, Sousa C, Araujo F, Fernandes A, Oliveira J, Passos-Coelho JL. Influence of the interval between the administration of doxorubicin and paclitaxel on the pharmacokinetics of these drugs in patients with locally advanced breast cancer. Cancer Chemother Pharmacol 2001; 48: 333-7.
44. Holmes FA, Rowinsky EK. Pharmacokinetic profiles of the doxorubicin in combination with taxanes. Semin Oncol 2001; 28 (4 Suppl. 12): 8-14.
45. Sheiner LB, Beal SL, Dunne A. Analysis of nonrandomly censored ordered categorical longitudinal data from analgesic trials. JASA 1997; 92: 1235-55.
46. Mccullugh P. Regression models for ordinal data. J Statistic Soc 1980; 42: 109-42.
47. Mandema JW, Stanski DR. Population pharmacodynamic model for keterolac analgesia. Clin Pharm Ther 1996; 60: 619-35.
48. Yafune A, Ishiguro M. Bootstrap approach for construction of confidence intervals for population pharmacokinetic parameters I. A use of Bootstrap standard error. Stat Med 1999; 18: 581-99.
49. Kleinbaum DG. Survival Analysis. New York: Springer-Verlag Inc. 1996: 95.
50. Klein JP. Survival Analysis: Techniques for Censored and Truncated Data. New York: Springer-Verlag Inc. 1997: 229-68.
51. Glantz SA, Slinker BA. Primer of Applied Regression and Analysis of Variance. New York: McGraw-Hill 1990: 225.
52. Smorenburg CH, Sparreboom A, Bontenbal M, Stoter G, Nooter K, Verweij J. Random crossover evaluation of body surface area-based dosing versus flat-fixed dosing of paclitaxel. J Clin Oncol 2003; 21: 197-202.
53. Grochow LB, Baraldi C, Noe D. Is dose normalization to weight or body surface area useful in adults? J Natl Cancer Inst 1990; 82: 323-5.
54. Egorin M. Horseshoes, hand grenades and body surface area-based dosing: aiming for a target. J Clin Oncol 2003;21: 182-3 (Editorial).
55. Ratain MJ. Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit? J Clin Oncol 1998; 16: 2297-8.
56. Sotaniemi EA, Arranto AJ, Pelkonen O, Pasanen M. Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther 1997; 161: 331-9.
57. Monsarrat B, Chatelut E, Royer I, Alvinerie P, DuBois J, Dezeuse A, Roche H, Cros S, Wright M, Canal P. Modification of paclitaxel metabolism in a cancer patient by induction of cytochrome P450 3A4. Drug Metab Dispos 1998; 26: 229-33.
58. Panday VR, Huizing MT, Willemse PH, De Graeff A, ten Bokkel Huinink WW, Vermorken JB, Beijnen JH. Hepatic metabolism of paclitaxel and its impact in patients with altered hepatic function. Semin Oncol 1997; 24: S11-34.
59. Venook AP, Egorin MJ, Rosner GL, Brown TD, Jahan TM, Batist G, Hohl R, Budman D, Ratain MJ, Kearns CM, Schilsky RL. Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction. Cancer and Leukemia Group B 9264. J Clin Oncol 1998; 16: 1811-9.
60. Hirth J, Watkins PB, Strawderman M, Schott A, Bruno R, Baker LH. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res 2000; 6: 1255-8.